CRISPRcharm-Kv2

CRISPRcharm-Kv2 is an experimental CRISPR-based epigenome-editing therapeutic developed by researchers at the University of California, Davis, for the treatment of Huntington's disease (HD). It utilizes a nuclease-deficient Cas9 (dCas9) platform fused to a KRAB repressor domain, specifically optimized to recruit endogenous DNMT3A to the huntingtin (HTT) gene promoter. This dual mechanism facilitates synergistic DNA methylation and H3K9me3 histone modification, resulting in robust and durable transcriptional silencing of HTT expression. CRISPRcharm-Kv2 is delivered via engineered virus-like particles (VLPs), which allow for the transient delivery of large CRISPR-effector complexes as ribonucleoproteins, thereby reducing the risk of long-term off-target effects and overcoming the packaging constraints of traditional viral vectors. In preclinical studies, this specific effector combination demonstrated superior silencing durability compared to standard CRISPRoff systems, persisting for over eight weeks in dividing cells.